Ownership

Mark Litton - CEO, Director at Athira Pharma, Inc.

Insider Transactions and Holdings

Entity Type: Individual
Role: CEO, Director
Stock Symbol: ATHA on Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
All Insider Reports: All Insider Reports

Mark Litton - trading volume in the past year for Athira Pharma, Inc.

	Shares	%	Avg Price	Total $
Buys
Sells	-9.64K	100%	$2.91	-$28.1K
Net	-9.64K	-100%		-$28.1K

Holdings reported by Mark Litton for Athira Pharma, Inc.

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	144K	$420K	$2.91	Jan 5, 2024	Direct
Common Stock	6.56K	$19.1K	$2.91	Jan 4, 2024	By Irrevocable Trust of OSL
Common Stock	6.56K	$19.1K	$2.91	Jan 4, 2024	By Irrevocable Trust of SWL
Common Stock	6.56K	$19.1K	$2.91	Jan 4, 2024	By Irrevocable Trust of WGL
Stock Option (Right to Buy)	650K			Feb 15, 2024	Direct	Common Stock

Transactions reported by Mark Litton for Athira Pharma, Inc.

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.